Complement activation in patients with systemic lupus erythematosus without nephritis

Rheumatology

Volumn 38, Issue 10, 1999, Pages 933-940

  Mollnes, T E ^a   Haga, H J ^b   Brun, J G ^b   Nielsen, E W ^a   Sjoholm A ^e   Sturfeldt, G ^e   Martensson U ^e   Bergh, K ^d   Rekvig, O P ^c  

^a NORDLAND HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Complement; Systemic lupus erythematosus; Terminal complement complex

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CORRELATION FUNCTION; DISEASE ACTIVITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032701607     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.10.933     Document Type: Article

References (42)

1. Lloyd W, Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) 1981;60:208-17.
2. Atkinson JP. Complement activation and complement receptors in systemic lupus erythematosus. [Review] Springer Semin Immunopathol 1986;9:179-94.
3. Walport MJ, Lachmann PJ. Complement deficiencies and abnormalities of the complement system in systemic lupus erythematosus and related disorders. Curr Opin Rheumatol 1990;2:661-3.
4. Agnello V. Lupus diseases associated with hereditary and acquired deficiencies of complement. [Review] Springer Semin Immunopathol 1986;9:161-78.
5. Wang Y, Hu QL, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996;93:8563-8.
6. Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: Why some tests fail. Arthritis Rheum 1996;39:370-8.
7. Sturfelt G, Johnson U, Sjöholm AG. Sequential studies of complement activation in systemic lupus erythematosus. Scand J Rheumatol 1985;14:184-96.
8. Jonsson H, Sturfelt G, Mårtensson U, Truedsson L, Sjöholm AG. Prospective analysis of C1 dissociation and complement activation in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1995;13:573-80.
9. Mollnes TE, Harboe M. Neoepitope expression during complement activation - a model for detecting antigenic changes in proteins and activation of cascades. Immunologist 1993;1:43-9.
10. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
11. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
12. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34:937-44.
13. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39:363-9.
14. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989;68: 141-50.
15. Gudmundsson S, Steinsson K. Systemic lupus erythematosus in Iceland 1975 through 1984. A nationwide epidemiological study in an unselected population. J Rheumatol 1990;17:1162-7.
16. Emlen W, Jarusiripipat P, Burdick G. A new ELISA for the detection of double-stranded DNA antibodies. J Immunol Methods 1990;132:91-101.
17. Rekvig OP, Moens U, Sundsfjord A, Bredholt G, Osei A, Haaheim H et al. Experimental expression in mice and spontaneous expression in human SLE of polyomavirus T-antigen - A molecular basis for induction of antibodies to DNA and eukaryotic transcription factors. J Clin Invest 1997;99:2045-54.
18. Siegert CE, Daha MR, van der Voort EA, Breedveld FC. IgG and IgA antibodies to the collagen-like region of C1q in rheumatoid vasculitis. Arthritis Rheum 1990; 33:1646-54.
19. Mårtensson U, Sjöholm AG, Sturfelt G, Truedsson L, Laurell AB. Western blot analysis of human IgG reactive with the collagenous portion of C1q: evidence of distinct binding specificities. Scand J Immunol 1992;35:735-44.
20. Mollnes TE, Høgåsen K, Hoaas BF, Michaelsen TE, Garred P, Harboe M. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties. Scand J Immunol 1995;41:449-56.
21. Mollnes TE. Analysis of in vivo complement activation. In: Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C, eds. Weir's handbook of experimental immunology, 5th edn. Boston: Blackwell Science, 1997:78.1-.8.
22. Nielsen EW, Johansen HT, Straume B, Mollnes TE. Effect of time, temperature and additives on a functional assay of C1 inhibitor. J Immunol Methods 1994;173:245-51.
23. Fure H, Nielsen EW, Hack CE, Mollnes TE. A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with Clr and Cls. Scand J Immunol 1997;46:553-7.
24. Wolbink GJ, Bollen J, Baars JW, Tenberge RJM, Swaak AJG, Paardekooper J et al. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 1993; 163:67-76.
25. Zilow G, Naser W, Friedlein A, Bader A, Burger R. Quantitation of C3a by ELISA using a monoclonal antibody to a neoantigenic C3a determinant. Prog Clin Biol Res 1989;308:299-304.
26. Bergh K, Iversen OJ. Production of monoclonal antibodies against the human anaphylatoxin-c5a des Arg and their application in the neoepitope-specific sandwich-ELISA for the quantification of C5a des Arg in plasma. J Immunol Methods 1992;152:79-87.
27. Wisnieski JJ, Jones SM. Comparison of autoantibodies to the collagen-like region of C1q in hypocomplementemic urticarial vasculitis syndrome and systemic lupus erythematosus. J Immunol 1992;148:1396-403.
28. Siegert CEH, Daha MR, Lobatto S, Vandervoort EAM, Breedveld FC. IgG autoantibodies to C1q do not detectably influence complement activation in vivo and in vitro in systemic lupus erythematosus. Immunol Res 1992; 11:91-7.
29. Sjöholm AG, Mârtensson U, Sturfelt G. Serial analysis of autoantibody responses to the collagen-like region of C1q, collagen type II, and double stranded DNA in patients with systemic lupus erythematosus. J Rheumatol 1997; 24:871-8.
30. Nakamura S, Yoshinari M, Saku Y, Hirakawa K, Miishima C, Murai K et al. Acquired C1 inhibitor deficiency associated with systemic lupus erythematosus affecting the central nervous system. Ann Rheum Dis 1991;50:713-6.
31. Jazwinska EC, Gatenby PA, Dunckley H, Serjeantson SW. C1 inhibitor functional deficiency in systemic lupus erythematosus (SLE). Clin Exp Immunol 1993;92:268-73.
32. Atkinson JP, German JC, Curd J, Hyla JF, Deegan MJ, Keren DF et al. Cold dependent activation of complement in systemic lupus erythematosus. A unique cause for a discrepancy between clinical and laboratory parameters. Arthritis Rheum 1981;24:592-601.
33. Lockshin MD, Qamar T, Redecha P, Harpel PC. Hypocomplementemia with low C1s-C1 inhibitor complex in systemic lupus erythematosus. Arthritis Rheum 1986;29:1467-72.
34. Charlesworth JA, Peake PW, Golding J, Mackie JD, Pussell BA, Timmermans V et al. Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus. Ann Rheum Dis 1989;48:153-9.
35. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986;45:359-66.
36. Schifferli JA, Bakkaloglu A, Amos N, Peters DK. C4-binding protein in sera of patients with systemic lupus erythematosus and mixed essential cryoglobulinemia. Complement 1984;1:81-6.
37. Barnum SR, Dahlbäck B. C4b-binding protein, a regulatory component of the classical pathway of complement, is an acute-phase protein and is elevated in systemic lupus erythematosus. Complement Inflamm 1990;7:71-7.
38. Mollnes TE. Biocompatibility: Complement as mediator of tissue damage and as indicator of incompatibility. Exp Clin Immunogenet 1997;14:24-9.
39. Rönnelid J, Gunnarsson I, Nilssonekdahl K, Nilsson B. Correlation between anti-C1q and immune conglutinin levels, but not between levels of antibodies to the structurally related autoantigens C1q and type II collagen in SLE or RA. J Autoimmun 1997;10:415-23.
40. Porcel JM, Ordi J, Castrosalomo A, Vilardell M, Rodrigo MJ, Gene T et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol Immunopathol 1995; 74:283-8.
41. Horigome I, Seino J, Sudo K, Kinoshita Y, Saito T, Yoshinaga K. Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases. Clin Exp Immunol 1987;70:417-24.
42. Auda G, Holme ER, Davidson JE, Zoma A, Veitch J, Whaley K. Measurement of complement activation products in patients with chronic rheumatic diseases. Rheumatol Int 1990;10:185-9.